Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain, and shortness of breath. Causes include cardiomyopathy, ischemic heart disease, and heart failure. Risk factors include age, family history, and medical history. Treatment includes antiarrhythmic medication.

The Ventricular Tachycardia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects.

Ventricular Tachycardia Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Ventricular Tachycardia pipeline drugs market are Beta 1 Adrenergic Receptor, Calcium Channel, Alpha 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Ion Channel, Peptidyl Prolyl Cis Trans Isomerase FKBP1A, Potassium Channel, Potassium Voltage Gated Channel Subfamily H Member 2, Ryanodine Receptor, and Ryanodine Receptor 2.

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Targets

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Targets

For more Ventricular Tachycardia pipeline drugs market target insights, download a free report sample

Ventricular Tachycardia Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the Ventricular Tachycardia pipeline drugs market are Beta 1 Adrenergic Receptor Antagonist, Calcium Channel Blocker, Alpha 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Ion Channel Blocker, Peptidyl Prolyl Cis Trans Isomerase FKBP1A Inhibitor, Potassium Channel Blocker, Potassium Voltage Gated Channel Subfamily H Member 2 Blocker, Ryanodine Receptor 2 Antagonist, Sodium Channel Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker.

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Mechanism of Actions

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the Ventricular Tachycardia pipeline drugs market, download a free report sample

Ventricular Tachycardia Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Ventricular Tachycardia pipeline drugs market are oral, inhalational, intravenous, and nasal.

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Routes of Administration

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Ventricular Tachycardia pipeline drugs market, download a free report sample

Ventricular Tachycardia Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Ventricular Tachycardia pipeline drugs market are Small Molecule and Gene Therapy.

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Molecule TypesVentricular Tachycardia Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Ventricular Tachycardia pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the Ventricular Tachycardia pipeline drugs market are ARMGO Pharma Inc, Academic Pharmaceuticals Inc, Elex Biotech LLC, GEXVal Inc, HUYA Bioscience International LLC, InCarda Therapeutics Inc, Milestone Pharmaceuticals Inc, Saliogen Therapeutics Inc, and Vivasc Therapeutics Inc.

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Companies

Ventricular Tachycardia Pipeline Drugs Market Analysis, by Companies

To know more about the Ventricular Tachycardia pipeline drugs market companies, download a free report sample

Ventricular Tachycardia Pipeline Drugs Market Report Overview

Key Targets Beta 1 Adrenergic Receptor, Calcium Channel, Alpha 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Ion Channel, Peptidyl Prolyl Cis Trans Isomerase FKBP1A, Potassium Channel, Potassium Voltage Gated Channel Subfamily H Member 2, Ryanodine Receptor, and Ryanodine Receptor 2
Key Mechanism of Actions Beta 1 Adrenergic Receptor Antagonist, Calcium Channel Blocker, Alpha 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Ion Channel Blocker, Peptidyl Prolyl Cis Trans Isomerase FKBP1A Inhibitor, Potassium Channel Blocker, Potassium Voltage Gated Channel Subfamily H Member 2 Blocker, Ryanodine Receptor 2 Antagonist, Sodium Channel Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker
Key Routes of Administration Oral, Inhalational, Intravenous, and Nasal
Key Molecule Types Small Molecule and Gene Therapy
Key Companies ARMGO Pharma Inc, Academic Pharmaceuticals Inc, Elex Biotech LLC, GEXVal Inc, HUYA Bioscience International LLC, InCarda Therapeutics Inc, Milestone Pharmaceuticals Inc, Saliogen Therapeutics Inc, and Vivasc Therapeutics Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Ventricular Tachycardia.
  • Reviews of pipeline therapeutics for Ventricular Tachycardia by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews key companies involved in Ventricular Tachycardia therapeutics and enlists all their major and minor projects.
  • Evaluation of Ventricular Tachycardia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Ventricular Tachycardia.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ventricular Tachycardia.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ventricular Tachycardia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Academic Pharmaceuticals Inc
ARMGO Pharma Inc
Elex Biotech LLC
GEXVal Inc
HUYA Bioscience International LLC
InCarda Therapeutics Inc
Milestone Pharmaceuticals Inc
Saliogen Therapeutics Inc
Vivasc Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ventricular Tachycardia – Overview

Ventricular Tachycardia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ventricular Tachycardia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ventricular Tachycardia – Companies Involved in Therapeutics Development

Academic Pharmaceuticals Inc

ARMGO Pharma Inc

Elex Biotech LLC

GEXVal Inc

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Milestone Pharmaceuticals Inc

Saliogen Therapeutics Inc

Vivasc Therapeutics Inc

Ventricular Tachycardia – Drug Profiles

amiodarone – Drug Profile

Product Description

Mechanism Of Action

History of Events

ARM-210 – Drug Profile

Product Description

Mechanism Of Action

History of Events

etripamil – Drug Profile

Product Description

Mechanism Of Action

History of Events

flecainide acetate – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia – Drug Profile

Product Description

Mechanism Of Action

HBI-3000 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Cardiomyopathies and Catecholaminergic Polymorphic Ventricular Tachycardia – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize Ryanodine Receptor 2 for Catecholaminergic Polymorphic Ventricular Tachycardia – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases – Drug Profile

Product Description

Mechanism Of Action

History of Events

soestelol – Drug Profile

Product Description

Mechanism Of Action

Ventricular Tachycardia – Dormant Projects

Ventricular Tachycardia – Discontinued Products

Ventricular Tachycardia – Product Development Milestones

Featured News & Press Releases

Apr 30, 2022: Milestone Pharmaceuticals announces presentation of data from phase 3 NODE-302 study of etripamil for the treatment of PSVT

Apr 21, 2022: Milestone Pharmaceuticals to host virtual key opinion leader event on etripamil for the treatment of PSVT

Nov 15, 2021: Milestone Pharmaceuticals announces presentation of heart rate analysis of NODE-301 trial of Etripamil in Patients with PSVT

May 17, 2021: Milestone Pharmaceuticals announces late-breaker oral presentation of NODE-301 data at ACC.21

Nov 18, 2020: Milestone Pharmaceuticals announces first patient enrolled in RAPID, a pivotal phase 3 study of etripamil in PSVT

Jul 23, 2020: Milestone Pharmaceuticals announces regulatory guidance and updated clinical development plan for Etripamil in PSVT

Mar 23, 2020: Milestone Pharmaceuticals announces topline results from first-of-its-kind phase 3 NODE-301 trial of etripamil for at-home acute PSVT treatment

Oct 03, 2019: Milestone Pharmaceuticals announces first patient enrolled in NODE-303 open-label safety study of Etripamil in PSVT

May 21, 2019: Milestone Pharmaceuticals presents studies on the economic impacts of PSVT at the ISPOR 2019 Annual Meeting

Apr 16, 2019: Milestone Pharmaceuticals appoints Paul Edick chairman of its board of directors

Apr 16, 2019: Milestone Pharmaceuticals appoints Paul Edick chairman of its board of directors

Aug 08, 2018: Milestone Pharmaceuticals announces first patient randomized in the phase 3 NODE-301 clinical trial evaluating Etripamil for termination of paroxysmal supraventricular tachycardia (PSVT) episodes

May 11, 2017: Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia

Apr 12, 2017: Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society’s 38th Annual Scientific Sessions

Mar 07, 2017: Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Ventricular Tachycardia, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Ventricular Tachycardia – Pipeline by Academic Pharmaceuticals Inc, 2022

Ventricular Tachycardia – Pipeline by ARMGO Pharma Inc, 2022

Ventricular Tachycardia – Pipeline by Elex Biotech LLC, 2022

Ventricular Tachycardia – Pipeline by GEXVal Inc, 2022

Ventricular Tachycardia – Pipeline by HUYA Bioscience International LLC, 2022

Ventricular Tachycardia – Pipeline by InCarda Therapeutics Inc, 2022

Ventricular Tachycardia – Pipeline by Milestone Pharmaceuticals Inc, 2022

Ventricular Tachycardia – Pipeline by Saliogen Therapeutics Inc, 2022

Ventricular Tachycardia – Pipeline by Vivasc Therapeutics Inc, 2022

Ventricular Tachycardia – Dormant Projects, 2022

Ventricular Tachycardia – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Ventricular Tachycardia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.